Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 2/20 | 0.56 |
| ▸ | ACP1 | P24666 | 8/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534314 | 1.00 | TACR3 (0.56) | TACR3ACP1SYK | |
| Hydrochloric Acid SCHEMBL6534629 | 0.99 | TACR3 (0.55) | TACR3ACP1SYK | |
| Hydrochloric Acid SCHEMBL6534632 | 0.99 | TACR3 (0.55) | TACR3ACP1SYK | |
| SCHEMBL6534377 | 0.95 | TACR3 (0.53) | TACR3ACP1SYK | |
| SCHEMBL6534374 | 0.95 | TACR3 (0.53) | TACR3ACP1SYK | |
| Hydrochloric Acid SCHEMBL6534586 | 0.94 | TACR3 (0.53) | TACR3ACP1SYK | |
| Hydrochloric Acid SCHEMBL6534588 | 0.94 | TACR3 (0.53) | TACR3ACP1SYK | |
| SCHEMBL6534428 | 0.94 | ACP1 (0.54) | TACR3ACP1 | |
| SCHEMBL6534431 | 0.94 | ACP1 (0.54) | TACR3ACP1 | |
| SCHEMBL17372662 | 0.94 | TACR3 (0.66) | TACR3ACP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154957-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACION PARA LA INVESTIG MEDICA APLICADA (ES) | 2019-11-20 | — | — | EP | claimed |
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-05-04 | — | — | US | claimed |
| EP-3154957-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2017-04-19 | — | — | EP | claimed |
| WO-2015192981-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2015-12-23 | — | — | WO | claimed |
| EP-1088818-B1 | Quinolin-4-yl derivatives | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | claimed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | claimed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | claimed |
| CN-106536509-B | Novel compounds as dual inhibitors of histone methyltransferase and DNA methyltransferase | 基础应用医学研究基金会 | 2020-06-09 | — | — | CN | disclosed |
| EP-3154957-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACION PARA LA INVESTIG MEDICA APLICADA (ES) | 2019-11-20 | — | — | EP | disclosed |
| US-9840500-B2 | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-12-12 | — | — | US | disclosed |
| US-9840500-B2 | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-12-12 | — | — | US | disclosed |
| US-9840500-B2 | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-12-12 | — | — | US | disclosed |
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-05-04 | — | — | US | disclosed |
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-05-04 | — | — | US | disclosed |
| EP-3154957-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015192981-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015192981-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2015-12-23 | — | — | WO | disclosed |
| EP-1088818-B1 | Quinolin-4-yl derivatives | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121316-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | DOT1L, DNMT3B, CARM1 | TACR3 4769/4885ACP1 3522/4885SYK 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.